References
1. Cairncross G, Wang M, Shaw E,
Jenkins R, Brachman D, Buckner J, et al. Phase III Trial of
Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of
RTOG 9402. Journal of Clinical Oncology. 2013;31(3):337-43.
2. Chang S, Zhang P, Cairncross JG,
Gilbert MR, Bahary JP, Dolinskas CA, et al. Phase III randomized study
of radiation and temozolomide versus radiation and nitrosourea therapy
for anaplastic astrocytoma: results of NRG Oncology RTOG 9813. Neuro
Oncol. 2017;19(2):252-8.
3. Stupp R, Hegi ME, Mason WP, van den
Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with
concomitant and adjuvant temozolomide versus radiotherapy alone on
survival in glioblastoma in a randomised phase III study: 5-year
analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-66.
4. Stupp R, Taillibert S, Kanner A,
Read W, Steinberg D, Lhermitte B, et al. Effect of Tumor-Treating Fields
Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on
Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
JAMA. 2017;318(23):2306-16.
5. van den Bent MJ, Baumert B, Erridge
SC, Vogelbaum MA, Nowak AK, Sanson M, et al. Interim results from the
CATNON trial (EORTC study 26053-22054) of treatment with concurrent and
adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a
phase 3, randomised, open-label intergroup study. Lancet.
2017;390(10103):1645-53.
6. Norden AD, Young GS, Setayesh K,
Muzikansky A, Klufas R, Ross GL, et al. Bevacizumab for recurrent
malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Neurology. 2008;70(10):779-87.
7. Taal W, Oosterkamp HM, Walenkamp
AM, Dubbink HJ, Beerepoot LV, Hanse MC, et al. Single-agent bevacizumab
or lomustine versus a combination of bevacizumab plus lomustine in
patients with recurrent glioblastoma (BELOB trial): a randomised
controlled phase 2 trial. Lancet Oncol. 2014;15(9):943-53.
8. Suchorska B, Weller M, Tabatabai G,
Senft C, Hau P, Sabel MC, et al. Complete resection of
contrast-enhancing tumor volume is associated with improved survival in
recurrent glioblastoma-results from the DIRECTOR trial. Neuro Oncol.
2016;18(4):549-56.
9. Chiocca EA, Nassiri F, Wang J,
Peruzzi P, Zadeh G. Viral and other therapies for recurrent
glioblastoma: is a 24-month durable response unusual? Neuro Oncol.
2019;21(1):14-25.
10. Kamiya-Matsuoka C, Gilbert MR.
Treating recurrent glioblastoma: an update. CNS Oncol. 2015;4(2):91-104.
11. Tsien CI, Pugh SL, Dicker AP,
Raizer JJ, Matuszak MM, Lallana EC, et al. NRG Oncology/RTOG1205: A
Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation
Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma. J Clin
Oncol. 2022:JCO2200164.
12. Naidoo J, Page DB, Wolchok JD.
Immune modulation for cancer therapy. Br J Cancer. 2014;111(12):2214-9.
13. Goldberg SB, Gettinger SN,
Mahajan A, Chiang AC, Herbst RS, Sznol M, et al. Pembrolizumab for
patients with melanoma or non-small-cell lung cancer and untreated brain
metastases: early analysis of a non-randomised, open-label, phase 2
trial. Lancet Oncol. 2016;17(7):976-83.
14. Combs SE, Thilmann C, Edler L,
Debus J, Schulz-Ertner D. Efficacy of fractionated stereotactic
reirradiation in recurrent gliomas: long-term results in 172 patients
treated in a single institution. J Clin Oncol. 2005;23(34):8863-9.
15. Nieder C, Astner ST, Mehta MP,
Grosu AL, Molls M. Improvement, clinical course, and quality of life
after palliative radiotherapy for recurrent glioblastoma. Am J Clin
Oncol. 2008;31(3):300-5.
16. Fogh SE, Andrews DW, Glass J,
Curran W, Glass C, Champ C, et al. Hypofractionated stereotactic
radiation therapy: an effective therapy for recurrent high-grade
gliomas. J Clin Oncol. 2010;28(18):3048-53.
17. Niyazi M, Sohn M, Schwarz SB,
Lang P, Belka C, Ganswindt U. Radiation treatment parameters for
re-irradiation of malignant glioma. Strahlenther Onkol.
2012;188(4):328-33.
18. Hudes RS, Corn BW, Werner-Wasik
M, Andrews D, Rosenstock J, Thoron L, et al. A phase I dose escalation
study of hypofractionated stereotactic radiotherapy as salvage therapy
for persistent or recurrent malignant glioma. Int J Radiat Oncol Biol
Phys. 1999;43(2):293-8.
19. Lugade AA, Sorensen EW, Gerber
SA, Moran JP, Frelinger JG, Lord EM. Radiation-induced IFN-gamma
production within the tumor microenvironment influences antitumor
immunity. J Immunol. 2008;180(5):3132-9.
20. Newcomb EW, Demaria S, Lukyanov
Y, Shao Y, Schnee T, Kawashima N, et al. The combination of ionizing
radiation and peripheral vaccination produces long-term survival of mice
bearing established invasive GL261 gliomas. Clin Cancer Res.
2006;12(15):4730-7.
21. Zeng J, See AP, Phallen J,
Jackson CM, Belcaid Z, Ruzevick J, et al. Anti-PD-1 blockade and
stereotactic radiation produce long-term survival in mice with
intracranial gliomas. Int J Radiat Oncol Biol Phys. 2013;86(2):343-9.
22. Vanpouille-Box C, Alard A,
Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, et al. DNA
exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity.
Nat Commun. 2017;8:15618.
23. Wen PY, Macdonald DR, Reardon DA,
Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment
criteria for high-grade gliomas: response assessment in neuro-oncology
working group. J Clin Oncol. 2010;28(11):1963-72.
24. Wainwright DA, Chang AL, Dey M,
Balyasnikova IV, Kim CK, Tobias A, et al. Durable therapeutic efficacy
utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice
with brain tumors. Clin Cancer Res. 2014;20(20):5290-301.
25. Onesti CE, Freres P, Jerusalem G.
Atypical patterns of response to immune checkpoint inhibitors:
interpreting pseudoprogression and hyperprogression in decision making
for patients’ treatment. J Thorac Dis. 2019;11(1):35-8.
26. Abdel-Wahab M, Pollack A.
Radiotherapy: encouraging early data for SBRT in prostate cancer. Nat
Rev Urol. 2009;6(9):478-9.
27. Brooks WH, Netsky MG, Normansell
DE, Horwitz DA. Depressed cell-mediated immunity in patients with
primary intracranial tumors. Characterization of a humoral
immunosuppressive factor. J Exp Med. 1972;136(6):1631-47.
28. Brooks WH, Roszman TL, Mahaley
MS, Woosley RE. Immunobiology of primary intracranial tumours. II.
Analysis of lymphocyte subpopulations in patients with primary brain
tumours. Clin Exp Immunol. 1977;29(1):61-6.
29. Dunn GP, Bruce AT, Ikeda H, Old
LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor
escape. Nat Immunol. 2002;3(11):991-8.
30. Dunn GP, Old LJ, Schreiber RD.
The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329-60.
31. Waziri A. Glioblastoma-derived
mechanisms of systemic immunosuppression. Neurosurg Clin N Am.
2010;21(1):31-42.
32. Schalper KA, Rodriguez-Ruiz ME,
Diez-Valle R, Lopez-Janeiro A, Porciuncula A, Idoate MA, et al.
Neoadjuvant nivolumab modifies the tumor immune microenvironment in
resectable glioblastoma. Nat Med. 2019;25(3):470-6.
33. Cloughesy TF, Mochizuki AY,
Orpilla JR, Hugo W, Lee AH, Davidson TB, et al. Neoadjuvant anti-PD-1
immunotherapy promotes a survival benefit with intratumoral and systemic
immune responses in recurrent glioblastoma. Nat Med. 2019;25(3):477-86.
34. Chongsathidkiet P, Jackson C,
Koyama S, Loebel F, Cui X, Farber SH, et al. Sequestration of T cells in
bone marrow in the setting of glioblastoma and other intracranial
tumors. Nat Med. 2018;24(9):1459-68.
35. Burnette BC, Liang H, Lee Y,
Chlewicki L, Khodarev NN, Weichselbaum RR, et al. The efficacy of
radiotherapy relies upon induction of type i interferon-dependent innate
and adaptive immunity. Cancer Res. 2011;71(7):2488-96.
36. Reits EA, Hodge JW, Herberts CA,
Groothuis TA, Chakraborty M, Wansley EK, et al. Radiation modulates the
peptide repertoire, enhances MHC class I expression, and induces
successful antitumor immunotherapy. J Exp Med. 2006;203(5):1259-71.
37. Klein B, Loven D, Lurie H,
Rakowsky E, Nyska A, Levin I, et al. The effect of irradiation on
expression of HLA class I antigens in human brain tumors in culture. J
Neurosurg. 1994;80(6):1074-7.
38. Garnett CT, Palena C, Chakraborty
M, Tsang KY, Schlom J, Hodge JW. Sublethal irradiation of human tumor
cells modulates phenotype resulting in enhanced killing by cytotoxic T
lymphocytes. Cancer Res. 2004;64(21):7985-94.
39. Laing RW, Warrington AP, Graham
J, Britton J, Hines F, Brada M. Efficacy and toxicity of fractionated
stereotactic radiotherapy in the treatment of recurrent gliomas (phase
I/II study). Radiother Oncol. 1993;27(1):22-9.
40. Hwang WL, Pike LRG, Royce TJ,
Mahal BA, Loeffler JS. Safety of combining radiotherapy with
immune-checkpoint inhibition. Nat Rev Clin Oncol. 2018;15(8):477-94.
41. Herbst RS, Soria JC, Kowanetz M,
Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to
the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature.
2014;515(7528):563-7.